509 related articles for article (PubMed ID: 21289519)
21. ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis.
Park S; Lee S; Kim J; Kim G; Park KH; Kim TU; Chung D; Lee H
PLoS One; 2019; 14(4):e0214867. PubMed ID: 30973901
[TBL] [Abstract][Full Text] [Related]
22. p73 and p63 regulate the expression of fibroblast growth factor receptor 3.
Sayan AE; D'Angelo B; Sayan BS; Tucci P; Cimini A; Cerù MP; Knight RA; Melino G
Biochem Biophys Res Commun; 2010 Apr; 394(3):824-8. PubMed ID: 20298673
[TBL] [Abstract][Full Text] [Related]
23. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
[TBL] [Abstract][Full Text] [Related]
24. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
[TBL] [Abstract][Full Text] [Related]
25. Expression of p63 and p73 in ameloblastomas.
Kumamoto H; Ohki K; Ooya K
J Oral Pathol Med; 2005 Apr; 34(4):220-6. PubMed ID: 15752257
[TBL] [Abstract][Full Text] [Related]
26. DeltaNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck.
Boldrup L; Coates PJ; Gu X; Nylander K
J Pathol; 2007 Dec; 213(4):384-91. PubMed ID: 17935121
[TBL] [Abstract][Full Text] [Related]
27. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
28. Overexpression and ratio disruption of ΔNp63 and TAp63 isoform equilibrium in endometrial adenocarcinoma: correlation with obesity, menopause, and grade I/II tumors.
Vakonaki E; Soulitzis N; Sifakis S; Papadogianni D; Koutroulakis D; Spandidos DA
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1271-8. PubMed ID: 22441934
[TBL] [Abstract][Full Text] [Related]
29. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
Orzol P; Holcakova J; Nekulova M; Nenutil R; Vojtesek B; Coates PJ
Histol Histopathol; 2015 May; 30(5):503-21. PubMed ID: 25510918
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
31. IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.
Venkatanarayan A; Raulji P; Norton W; Chakravarti D; Coarfa C; Su X; Sandur SK; Ramirez MS; Lee J; Kingsley CV; Sananikone EF; Rajapakshe K; Naff K; Parker-Thornburg J; Bankson JA; Tsai KY; Gunaratne PH; Flores ER
Nature; 2015 Jan; 517(7536):626-30. PubMed ID: 25409149
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of p53, p63 and p73 protein and mRNA for DMBA-induced hamster buccal-pouch squamous-cell carcinomas.
Chen YK; Huse SS; Lin LM
Int J Exp Pathol; 2004 Apr; 85(2):97-104. PubMed ID: 15154915
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis.
Choi HR; Batsakis JG; Zhan F; Sturgis E; Luna MA; El-Naggar AK
Hum Pathol; 2002 Feb; 33(2):158-64. PubMed ID: 11957139
[TBL] [Abstract][Full Text] [Related]
34. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis.
Geddert H; Kiel S; Heep HJ; Gabbert HE; Sarbia M
Hum Pathol; 2003 Sep; 34(9):850-6. PubMed ID: 14562279
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73.
Venkatanarayan A; Raulji P; Norton W; Flores ER
Cell Cycle; 2016; 15(2):164-71. PubMed ID: 26652033
[TBL] [Abstract][Full Text] [Related]
36. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis.
King KE; Ponnamperuma RM; Gerdes MJ; Tokino T; Yamashita T; Baker CC; Weinberg WC
Carcinogenesis; 2006 Jan; 27(1):53-63. PubMed ID: 16081516
[TBL] [Abstract][Full Text] [Related]
37. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
38. Alterations of p63 and p73 in human cancers.
Inoue K; Fry EA
Subcell Biochem; 2014; 85():17-40. PubMed ID: 25201187
[TBL] [Abstract][Full Text] [Related]
39. p63 and p73: roles in development and tumor formation.
Moll UM; Slade N
Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
[TBL] [Abstract][Full Text] [Related]
40. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance.
Hong SM; Cho H; Moskaluk CA; Yu E; Zaika AI
J Mol Histol; 2007 Jun; 38(3):167-75. PubMed ID: 17385050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
